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Articles
Treatment of community-onset, childhood convulsive 
status epilepticus: a prospective, population-based study
Richard F M Chin, Brian G R Neville, Catherine Peckham, Angie Wade, Helen Bedford, Rod C Scott
Background Episodes of childhood convulsive status epilepticus (CSE) commonly start in the community. Treatment 
of CSE aims to minimise the length of seizures, treat the causes, and reduce adverse outcomes; however, there is a 
paucity of data on the treatment of childhood CSE. We report the ﬁ ndings from a systematic, population-based study 
on the treatment of community-onset childhood CSE.  
Methods We collected data prospectively on children in north London, UK, who had episodes of CSE (ascertainment 
62–84%). The factors associated with seizure termination after ﬁ rst-line and second-line therapies, episodes of CSE 
lasting for longer than 60 min, and respiratory depression were analysed with logistic regression. Analysis was per 
protocol, and adjustment was made for repeat episodes in individuals.
Results 182 children of median age 3·24 years (range 0·16–15·98 years) were included in the North London Convulsive 
Status Epilepticus in Childhood Surveillance Study (NLSTEPSS) between May, 2002, and April, 2004. 61% (147) of 
240 episodes were treated prehospital, of which 32 (22%) episodes were terminated. Analysis with multivariable 
models showed that treatment with intravenous lorazepam (n=107) in the accident and emergency department was 
associated with a 3·7 times (95% CI 1·7–7·9) greater likelihood of seizure termination than was treatment with rectal 
diazepam (n=80). Treatment with intravenous phenytoin (n=32) as a second-line therapy was associated with a 9 times 
(95% CI 3–27) greater likelihood of seizure termination than was treatment with rectal paraldehyde (n=42). No 
treatment prehospital (odds ratio [OR] 2·4, 95% CI 1·2–4·5) and more than two doses of benzodiazepines 
(OR 3·6, 1·9–6·7) were associated with episodes that lasted for more than 60 min. Treatment with more than two 
doses of benzodiazepines was associated with respiratory depression (OR 2·9, 1·4–6·1). Children with intermittent 
CSE arrived at the accident and emergency department later after seizure onset than children with continuous CSE 
did (median 45 min [range 11–514 min] vs 30 min [5–90 min]; p<0·0001, Mann-Whitney U test); for each minute delay 
from onset of CSE to arrival at the accident and emergency department there was a 5% cumulative increase in the risk 
of the episode lasting more than 60 min. 
Interpretation These data add to the debate on optimum emergency treatment of childhood CSE and suggest that the 
current guidelines could be updated. 
Funding An anonymous donor to UCL Institute of Child Health; the Wellcome Trust; UK Department of Health 
National Institute for Health Research Biomedical Research Centres Funding Scheme; Medical Research Council.
Introduction
Convulsive status epilepticus (CSE) is the most common 
neurological emergency of childhood, with an incidence 
of between 17 and 23 per 100 000 children per year.1 CSE 
is deﬁ ned as either two or more convulsions 
without complete recovery of consciousness between 
seizures (intermittent CSE) or as a single prolonged 
seizure that lasts at least 30 min (continuous CSE).2 
CSE is associated with epilepsy later in life and cognitive 
and behavioural impairments.3 The treatment of CSE 
aims to minimise the length of seizures and treat the 
causes, thereby reducing adverse outcomes. Eﬀ ective 
treatment of the seizures requires early and robust 
pharmacological intervention and recognition of the 
predictors of prolonged seizures that can be modiﬁ ed. 
There are four phases for CSE management: 
prehospital; ﬁ rst-line treatment in the accident and 
emergency department; second-line treatment after the 
failure or absence of benzodiazepine ﬁ rst-line therapy; 
and general anaesthesia. However, there is a paucity of 
data on the beneﬁ ts of prehospital treatment and the 
choice and route of administration of antiepileptic drugs 
(AEDs) in hospital.4,5 Furthermore, the predictors of 
respiratory depression, which is an important 
complication of the treatment of CSE, are inadequately 
researched.6,7 Neither of the current UK treatment 
guidelines—the Advanced Paediatric Life Support (APLS) 
guidelines and the National Institute for Health and 
Clinical Excellence (NICE) guidelines—cover the 
prehospital setting, despite most episodes of CSE starting 
in the community.8,9 Both guidelines recommend similar 
hospital treatments, despite the absence of good evidence 
for treatments for CSE.4 
The investigators in a prospective, population-based 
study of childhood CSE—the North London Convulsive 
Status Epilepticus in Childhood Surveillance Study 
(NLSTEPSS)—recruited between 62% and 84% of all 
potentially eligible children in north London who had 
CSE.1 The treatment given to the children in this group 
whose CSE began in the community was analysed. Our 
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aims were to characterise the treatments given 
prehospital and in the accident and emergency 
department; identify the factors that are associated with 
seizure termination after ﬁ rst-line treatment in the 
accident and emergency department; identify the factors 
that are associated with seizure termination after second-
line treatment in those children who failed to respond to 
or who had not received benzodiazepine therapy; 
determine which factors are associated with seizures 
that last for more than 60 min; and identify the predictors 
of respiratory depression. 
Methods
Patients
Clinical and demographic data were collected 
prospectively between May 1, 2002, and April 30, 2004, on 
children aged between 29 days and 15 years who lived in 
north London and had episodes of CSE. Children who 
were eligible were identiﬁ ed through a multisource 
identiﬁ cation system that involved the clinical network 
that provided medical services for north London. Home 
postcodes were used to validate the children’s residency 
in north London and to establish their IMD2004 (index 
of multiple deprivation 2004) score—a measure of the 
socioeconomic status for the area in which each child 
lived. IMD2004 scores, which are used by the UK 
government to direct policy and allocate resources, are 
the combined sums of the weighted, exponentially 
transformed scores of seven separate measures of 
deprivation (income, employment, health, education, 
housing, crime, and living environment). The higher the 
IMD2004 score, the more deprived the area is; however, 
because of the exponential distribution the scale is not 
linear, and an area with a score of 40 is not necessarily 
twice as deprived as an area with a score of 20.10 
Procedures
Data on each child who was eligible were obtained 
within 2 weeks of their identiﬁ cation, through a 
standardised CSE admission pro forma from copies of 
the accident and emergency, nursing, ambulance, and 
intensive care notes, and by direct interview with the 
attending doctors, nurses, and paramedics. The aetiology 
of CSE and whether there were focal features were 
determined, irrespective of the age of the patient, by two 
of the investigators (RFMC and RCS) on the basis of the 
history obtained from carers and by direct observation 
or examination by the medical team. When the assessors 
disagreed on the classiﬁ cation, conﬂ icts were resolved 
by consensus or by third-party adjudication. Details of 
the study methods have been described previously.1 The 
study was approved by the London Multicentre Research 
Ethics Committee and the local research ethics 
committees of each health district involved. Because 
NLSTEPSS was a surveillance study and all data were 
anonymised, neither the patients nor their families 
provided written or verbal informed consent. There 
were no missing data. Treatment decisions were made 
by individual carers, paramedics, and the doctors who 
enrolled the patients, and not by the research team. 
Seizure termination was deﬁ ned as termination of overt 
clinical seizure activity within 10 min of the completion 
of the administration of AEDs.11,12 Seizure duration was 
deﬁ ned as the interval between the reported onset of 
CSE and cessation of clinical seizure activity. Data 
obtained from the standardised CSE admission pro 
forma questionnaire included the time at which the 
carer ﬁ rst recognised seizure activity, the time at which 
the emergency medical services recorded being called, 
the time they arrived at the children, the time of their 
arrival at the accident and emergency department, and 
the time of seizure termination.
The adequacy of the doses of AEDs was deﬁ ned by the 
doses recommended in the third edition of the APLS 
guideline,13 which was the version that was applicable 
during the study: 0·1 mg per kg for intravenous 
lorazepam; 0·5 mg per kg for rectal diazepam; 
0·4 mL per kg for rectal paraldehyde; 18 mg per kg for 
intravenous phenytoin; and 15–20 mg per kg for 
intravenous phenobarbitone. Bodyweight, as estimated 
by staﬀ  in the accident and emergency department, was 
used to estimate the adequacy of doses. Doses that were 
lower than 80% and higher than 120% of the adequacy 
doses were deﬁ ned as either inadequate (low) or high.6 
Statistical analysis 
All analyses were done with SPSS version 15.0 (Chicago, 
IL, USA), StatXact version 4.0 (Cytel, MA, USA), or Stata 
SE version 9.0 (Stata, TX, USA). Logistic regression 
analyses were done to identify the factors that are 
associated with seizure termination after ﬁ rst-line 
treatment in the accident and emergency department; 
the factors associated with seizure termination after 
second-line treatment in those children who failed to 
respond to or who never received ﬁ rst-line benzodiazepine 
therapy; the factors that are associated with seizures that 
last for more than 60 min; and the factors that predict 
respiratory depression. 
The univariate factors that were signiﬁ cantly associated 
with outcomes were identiﬁ ed, and whether these were 
independent was calculated with multivariable models. 
Any factors that were not signiﬁ cant were included in the 
models, to identify the factors that were associated with 
outcome only after adjustment for other factors. All 
episodes were included in the analysis, and the correlation 
between repeat episodes in the same child was adjusted 
for by the incorporation of the child as a random factor.14 
The anthropometric factors that were assessed for all 
aims were age, ethnic group, sex, and IMD2004 scores. 
First-ever versus a history of CSE, intermittent versus 
continuous CSE, whether there were focal features, the 
aetiology of CSE, and whether the child was neurologically 
healthy before the onset of CSE were also recorded. With 
regards to treatment, we recorded whether the child had 
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prehospital treatment or not, whether they had prehospital 
treatment within 15 min of the onset of CSE or not, the 
adequacy of dose of the ﬁ rst AED given prehospital, the 
time between onset of CSE and arrival at the accident and 
emergency department, the choice of AED (rectal 
diazepam, intravenous lorazepam, or other) on arrival at 
the accident and emergency department, the adequacy of 
the dose of the ﬁ rst-line AED given in the accident and 
emergency department, and the time between the arrival 
in the accident and emergency department and when the 
ﬁ rst AED was given. To identify the factors that were 
associated with seizure termination in the children who 
needed second-line treatment, the factors that were 
associated with seizures that lasted for more than 60 min, 
and the factors that predict respiratory depression, we 
investigated the choice of second-line AED (rectal 
paraldehyde, intravenous phenytoin, or other) and 
whether more than two doses of benzodiazepines, 
compared with two or fewer doses, were given. 
Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, data interpretation, or report 
writing. The corresponding author had full access to all 
the study data and ﬁ nal responsibility for the decision to 
submit for publication.
Results
240 episodes of CSE that started in the community 
were identiﬁ ed in 182 children (ﬁ gure). Table 1 shows 
the characteristics of these children. Most episodes of 
CSE (69%) occurred in children who had pre-existing 
neurological abnormalities. Details of the causes of 
CSE in NLSTEPSS have been described previously.1
Although not a part of the APLS guidelines, prehospital 
treatment was given before arrival at the accident and 
emergency department in 61% of episodes (ﬁ gure). Of 
these, 93 (63%) were treated by the paramedics and 54 
(37%) were treated by their carers. Rectal diazepam was 
the most commonly given treatment (141 episodes [96%]). 
The seizures were terminated in response to prehospital 
treatment in 37 episodes (25%), 43 (29%) episodes were 
treated with two or more doses of rectal diazepam, and in 
four of the six episodes that were treated with more than 
two doses of rectal diazepam the patients had respiratory 
depression while being transported to the accident and 
emergency department. Of the 141 episodes that were 
treated with rectal diazepam, 106 (75%) were treated with 
a dose that was lower than the 0·5 mg per kg 
recommended in the APLS guidelines for treatment on 
arrival at the accident and emergency department.13 Low-
dose treatment was given by carers in 38 of 48 episodes 
and by paramedics in 68 of 93 episodes (79% vs 73%; 
diﬀ erence 6%, 95% CI –10% to 19%). 35 of 48 children 
who had episodes of CSE before enrolment were given 
prehospital treatment by carers, whereas 71 of 93 ﬁ rst-
ever episodes of CSE were treated, in the ﬁ rst instance, 
by paramedics. The children with ﬁ rst-ever CSE who 
were initially treated by their carers had pre-existing 
neurological abnormalities, including epilepsy, and had 
been prescribed rectal diazepam for prolonged seizures. 
83 of 106 episodes that were treated with low doses had 
Episodes (n=240) Children (n=182) 
Age (years) 3·24 (0·16–15·98) 3·24 (0·16–15·98)
IMD2004 score 36·15 (6·06–70·9) 36·01 (6·06–70·90)
Time from onset to arrival 
at accident and emergency 
(min)
35 (5–514) 39 (5–514)
Duration of seizure (min)  65 (30–975) 70 (30–975)
White:non-white 95:145 (40%:60%) 65:117 (36%:64%) 
Male:female 110:130 (46%:54%) 88:94 (48%:52%)
First-ever seizure:history of 
seizures 
138:102 (58%:42%) 138:44 (76%:24%)
Intermittent seizures:
continuous seizures
109:131 (45%:55%) 90:92 (49%:51%)
Focal features 84 (35%) 59 (32%)
Previously neurologically 
healthy
75 (31%) 71 (39%)
Prehospital treatment 
within 15 min of onset
68 (28%) 43 (24%)
Data are median (range) or n (%). IMD2004=index of multiple deprivation 2004.
Table 1: Characteristics of episodes and children with CSE
93 episodes not treated before reaching hospital 147 episodes treated before reaching hospital
240 episodes of CSE
5 seizure terminations 32 seizure terminations
203 episodes treated on arrival at accident and 
         emergency department
121 seizure terminations after ﬁrst-line AEDs
        63 after treatment with intravenous lorazepam
        56 after treatent with rectal diazepam
82 episodes treated with second-line AEDs
      42 treated with rectal paraldehyde
      32 treated with intravenous phenytoin
         5 treated with intravenous phenobarbitone
         3 treated with thiopentone
41 seizure terminations after second-line AEDs
41 episodes treated with thiopentone
187 treated with ﬁrst-line AEDs
         107 treated with intravenous lorazepam
           80 treated with rectal diazepam
Figure: Trial proﬁ le
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seizure activity on arrival at accident and emergency, 
compared with 30 of 35 episodes that were treated with 
the recommended doses. 
203 episodes required treatment on arrival at accident 
and emergency, which is the starting point of the national 
APLS guidelines. 107 episodes (53%) were treated with a 
mean dose of 0·1 mg per kg intravenous lorazepam (mean 
diﬀ erence from recommended dose 0 mg per kg [95% CI 
–0·01 to 0·01 mg per kg]) and 80 episodes (39%) were 
treated with a mean dose of 0·25 mg per kg rectal diazepam 
(0·26 mg per kg [0·22 to 0·30 mg per kg]), which are the 
ﬁ rst-line treatments recommended in the APLS guideline 
for the accident and emergency setting. The median time 
from arrival at accident and emergency to treatment with 
intravenous lorazepam was longer than the median time 
to treatment with rectal diazepam (7 min [1–23 min] vs 
4 min [1–16 min]; p=0·005, Mann-Whitney U test). 
16 episodes were not treated with the standard ﬁ rst-line 
therapy of benzodiazepines: 13 were treated with second-
line therapy (nine with rectal paraldehyde, four with 
phenobarbitone) and three were treated with thiopentone 
as an anaesthetic (ﬁ gure). These episodes occurred in 
four children with epilepsy-related CSE (one child had 
eight episodes, two children had two episodes each, and 
one child had one episode) who had episodes of CSE that 
did not respond to benzodiazepines. 
The choice of AED and the adequacy of the dose were 
the only factors that were associated with seizure 
termination within 10 min of giving the ﬁ rst AED on 
arrival at accident and emergency as assessed with 
univariate analysis, and these factors were independently 
associated with seizure termination. In the multivariable 
analysis, treatment with intravenous lorazepam was 
more eﬀ ective than was treatment with rectal diazepam, 
particularly if the dose was adequate (table 2).
Of the 127 episodes that continued beyond 10 min after 
the ﬁ rst benzodiazepine was given, 107 (84%) were treated 
with further doses of benzodiazepines and 20 (16%) were 
treated with second-line treatment. A mean dose of 
0·08 mg per kg intravenous lorazepam (mean diﬀ erence 
from recommended dose 0·22 mg per kg, 95% CI 0·01–
0·03 mg per kg) was the most common (n=90) second-line 
benzodiazepine given in hospital, and this treatment led to 
17 seizure terminations. By contrast, only one of 16 episodes 
that were treated with a second dose of rectal diazepam 
(mean dose 0·21 mg per kg; mean diﬀ erence from 
recommended dose 0·30 mg per kg, 95% CI 
0·27–0·33 mg per kg) had seizure termination.
Of 82 episodes treated with a second-line AED, only 
42 episodes were treated initially with the APLS-
recommended AED, rectal paraldehyde (mean dose 
0·28 mL per kg; mean diﬀ erence from recommended 
dose 0·12 mL per kg, 95% CI 0·10–0·14 mL per kg). 32 of 
82 episodes were treated with intravenous phenytoin 
(mean dose 12·4 mg per kg; mean diﬀ erence from 
recommended dose 5·5 mg per kg, 95% CI 3·2–7·7 mg 
per kg). There were no statistically signiﬁ cant diﬀ erences 
in the patient and seizure characteristics between groups. 
Two of the 42 children who were treated with paraldehyde 
had further clinical seizure activity within 4 h of CSE 
termination compared with none of the children in the 
other groups. No episode was treated with fosphenytoin.
Table 3 shows the factors that were identiﬁ ed by univariate 
and multivariate analyses as being signiﬁ cantly associated 
with increased seizure terminations after second-line AED 
and the likelihood of seizure termination after phenytoin 
compared with paraldehyde. No other factors were 
independently associated with seizure termination after the 
choice of initial second-line AED was taken into account.
Of 240 episodes, 44 (18%) required anaesthesia for 
seizure termination. Further analysis was precluded 
because all patients that required anaesthesia were 
treated with thiopentone.
The factors that were identiﬁ ed as signiﬁ cant in 
univariate and multivariate analyses for episodes of 
Univariate         
odds ratio (95% CI)
p Adjusted               
odds ratio (95% CI)
p
Rectal diazepam 1·00 ·· ·· ··
Intravenous lorazepam 3·49 (1·53–7·99) 0·003 3·7 (1·7–7·9) 0·001
Other 1·83 (0·51–6·64) 0·36 1·5 (0·4–6·1) 0·60
Adequate vs low dose of ﬁ rst-line AED given 
at accident and emergency department
1·00 (1·00–1·00) 0·05 1·002 (1·000–1·003) 0·04
··=not applicable. AED=antiepileptic drug.
Table 2: Univariable and multivariable logistic regression of seizure termination after treatment with 
ﬁ rst-line AED at accident and emergency department (n=203)
Univariate odds 
ratio (95% CI)
p Adjusted odds 
ratio (95% CI)
p
Male vs female 1·8 (1·2–2·4) 0·045 ·· ··
No prehospital treatment vs prehospital 
treatment
3·1 (1·1–3·8) 0·001 2·4 (1·2–4·5) 0·008
Time from onset of CSE to arrival at accident 
and emergency department (min)
1·03 (1·02–1·08) <0·0001 1·05 (1·03–1·06) <0·0001
More than two doses of benzodiazepines vs 
one or two doses of benzodiazepines
3·2 (1·6–7·2) 0·0025 3·6 (1·9–6·7) <0·0001
Intermittent vs continuous CSE 3·0 (1·2–5·2) <0·0001 2·5 (1·4–4·8) 0·003
··=not applicable.
Table 4: Logistic regression analyses of factors associated with CSE that lasted for longer than 60 min 
compared with CSE that lasted for 30–60 min (n=240)
Univariate odds 
ratio (range)
p Adjusted odds 
ratio (range)
p
Male vs female 3·3 (1·3–5·1) 0·054 ·· ··
First ever CSE vs history of CSE 2·1 (1·4–4·8) 0·055 ·· ··
Prehospital treatment vs no treatment 2·7 (1·9–5·4) 0·051 ·· ··
Intravenous phenytoin vs rectal paraldehyde 
as initial second-line AED
10·2 (2·4–31·2) <0·0001 8·9 (3·0–27·0) p<0·0001
··=not applicable. AED=antiepileptic drug.
Table 3: Logistic regression analyses of the factors that are associated with respiratory depression
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CSE that lasted longer than 60 min are shown in table 
4. For each minute delay from the onset of CSE to 
arrival at the accident and emergency department there 
was a 5% (95% CI 3–6%) cumulative increased risk of 
CSE lasting longer than 60 min (p<0·0001). Thus, 
arrival at the accident and emergency department 
40 min after the onset of CSE, irrespective of prehospital 
treatment, was associated with a 4·3 times greater 
likelihood of an episode of CSE lasting longer than 
60 min compared with arrival within 10 min of onset 
(4·3=1·05⁴⁰–¹⁰=1·05³⁰).
Of the 229 children treated with benzodiazepines, 
120 (52%) received one or two doses and 109 (48%) 
received more than two doses. Children given prehospital 
treatment were more likely to be treated with more than 
two doses of benzodiazepines (81 of 147) compared with 
those who had their ﬁ rst treatment in the accident and 
emergency department (28 of 88 [diﬀ erence 23%, 
95% CI 10–35%; p=0·001]).
Episodes of intermittent CSE were 2·5 times (95% CI 
1·4–4·8) more likely to last longer than 60 min compared 
with episodes of continuous CSE (p=0·003). To 
investigate whether this was related to inadequate 
recognition of CSE or to the management strategies, we 
compared the time intervals between the onset of CSE 
and the call to emergency medical services, the time 
between the call and the arrival of emergency medical 
services, and the time of arrival of emergency medical 
services and arrival at the accident and emergency 
department. 
Children with intermittent CSE arrived at the accident 
and emergency department longer after the onset of CSE 
than the children with continuous CSE did (median 
45 min [range 11–514 min] vs 30 min [5–90 min]; 
p<0·0001, Mann-Whitney U test). One child who arrived 
at accident and emergency 514 min after the onset of CSE 
had epilepsy and severe developmental delay and had 
been having intermittent seizures without recovery 
between convulsions, but the relevance of this was not 
recognised. Emergency medical services were called later 
for episodes of intermittent CSE than for episodes of 
continuous CSE (15 min [0–495 min] vs 5 min [1–39 min]; 
p<0·0001). There were no diﬀ erences in emergency 
medical services response times (p=0·81, Mann-Whitney 
U test), but children with intermittent CSE arrived at the 
accident and emergency departments later than those 
with continuous CSE did (median time 20 min [range 
2–100 min] vs 15·5 min [5–43 min]; p=0·037, Mann-
Whitney U test). Similar proportions of children with 
intermittent CSE received prehospital treatment (95 of 
187 [51%]) compared with children with continuous CSE 
(96 of 187 [49%]), and there was no diﬀ erence between 
the groups in the speed of giving prehospital treatment. 
Respiratory depression, which is deﬁ ned as a fall in 
oxygen saturation below 92% in room air and a decrease in 
respiratory eﬀ ort that requires assisted breathing at any 
point from the onset of CSE to seizure termination, was 
identiﬁ ed in 41 episodes (17%). Treatment with more than 
two doses of benzodiazepines and increasing socioeconomic 
deprivation were signiﬁ cantly associated on univariate 
analysis with respiratory depression (table 5). Each unit 
increase in the IMD2004 score has a 3% increased risk of 
CSE: a 30 point diﬀ erence in IMD2004 scores would 
increase the risk of CSE 2·4 fold (1·03³⁰). 
Discussion 
The results of this study provide systematic population-
based data on the treatment of community-onset 
childhood CSE. These data add to the clinical debate on 
the appropriateness of current pharmacological 
interventions to treat potentially modiﬁ able risk factors 
for seizures lasting longer than 60 min and for respiratory 
depression. Although there is a risk of reporting bias, 
particularly with regard to the start and end times of the 
episodes of CSE, this was minimised through our design 
of a population-based study with high ascertainment, 
prospective and early collection of data, the use of a 
standardised admission pro forma and copies of medical 
reports that were anonymous, direct interviews with 
medical staﬀ , and construction of individual timelines as 
recorded by the emergency medical services and the 
accident and emergency department staﬀ . 
Treatment guidelines for CSE have previously been 
directed to the treatment of CSE in the hospital; however, 
because most childhood seizures start in the community, 
prehospital treatment should have an important role. 
Prehospital treatment reduced seizure duration in 
hospital-based studies in children and adults,15,16 and our 
data provide evidence that prehospital treatment in 
children who have seizures that last for at least 30 min 
might also reduce seizure length. However, prehospital 
treatment given by emergency medical service personal 
is not a universal practice, and even when prehospital 
treatment is included in emergency treatment guidelines 
it is not always given.6 In north London, the London 
Ambulance Service has a policy of giving rectal diazepam 
to children with seizures, although this is not included in 
the UK APLS guidelines.17 Despite this treatment, a third 
of the children in our cohort did not receive prehospital 
treatment. Because most children had ﬁ rst-ever CSE and 
were previously neurologically healthy, prehospital 
treatment could only have been given by the emergency 
medical services. Therefore, giving benzodiazepines in 
the community to children with seizures might reduce 
Univariate odds 
ratio (95% CI)
p Adjusted odds 
ratio (95% CI)
p
More than two doses of benzodiazepines vs  
two or fewer doses of benzodiazepines
3·2 (1·3–7·4) 0·031 2·9 (1·4–6·1) 0·02
IMD2004 1·01 (1·00–1·04) 0·024 1·03 (1·00–1·05) 0·03
IMD2004=index of multiple deprivation 2004. 
Table 5: Logistic regression analyses of the factors that are associated with respiratory depression
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seizure length and adverse outcomes. Although rectal 
diazepam was the AED used most commonly in our 
study, data suggest that buccal midazolam might become 
the preferred treatment in this setting.18–21
In our study, intermittent CSE was as common as 
continuous CSE was but not as well recognised or 
managed: carers delayed seeking help, arrival at accident 
and emergency departments was later, and a greater 
proportion of episodes lasted for more than 60 min. An 
emergency medical services protocol that advises against 
the treatment of seizures that have “stopped” might 
contribute to under-recognition of intermittent CSE. 
Because responses to prehospital treatment cannot be 
predicted, early transport to hospital is paramount; the 
longer a seizure lasts, the harder it is to stop.22,23 Early 
transport to hospital enables inadequate prehospital 
doses to be topped up, quicker ﬁ rst-line treatment to be 
given to children who have not been treated, and the use 
of other AEDs in those children with seizures that are 
refractory to benzodiazepines. 
We only studied children who were taken to an accident 
and emergency department after having a seizure or 
series of seizures and did not recover consciousness for 
at least 30 min. Therefore, children with seizures who 
were successfully treated by their carers or paramedics 
and who did not need to attend hospital were excluded, 
which could explain the substantially lower response rate 
to rectal doses of diazepam compared with the response 
rates reported elsewhere.24
A Cochrane Review of the treatment of childhood CSE 
found only one eligible study,4 in which the authors 
compared intravenous diazepam with intravenous 
lorazepam as the ﬁ rst-line treatment in hospital25 and 
suggested that these drugs were similar in eﬃ  cacy. 
However, no data to compare rectal diazepam with 
intravenous lorazepam (the drugs recommended by 
APLS and NICE) are reported. Our data suggest that 
intravenous lorazepam is associated with a greater 
likelihood of seizure termination than rectal diazepam 
is, without increased risk of respiratory depression. The 
onset of CSE is not always witnessed, and there is 
evidence of ongoing electrical seizure activity seen on 
EEG in a few patients after all clinical seizure activity 
has stopped, although such activity is unlikely if there is 
evidence of quick recovery.25 EEG monitoring is not 
widely available in the hospitals that participated in this 
study; therefore, we had to rely on the clinical expertise 
of the attending doctors. Patients in whom overt seizure 
activity stopped and who showed clinical evidence of 
recovery shortly afterwards were deemed to have had 
seizure termination. Continued seizure activity was 
presumed if they did not show evidence of recovery and 
they were managed accordingly. Our approach, which 
established the start and end times of seizure activity in 
CSE, is similar to the one used in other studies,15,16,26 
thereby increasing the general applicability of our 
results. 
The authors of studies in young children suggest that a 
single rectal dose of 0·5 mg per kg of diazepam or a 
single intravenous dose of 0·1 mg per kg of lorazepam 
can provide levels of either AED that are eﬀ ective to stop 
convulsions within 3 min of them being given, but there 
is substantial variation in absorption by the rectal 
route.27–30 In this study, children who were treated with 
intravenous lorazepam were treated later after onset of 
CSE and on arrival at hospital than children who were 
treated with rectal diazepam, but they still had a greater 
likelihood of seizure termination. Taken together, these 
data suggest that the speed of action of AEDs alone is 
unlikely to explain the observed diﬀ erences between 
intravenous and rectal treatment. 
We have shown that intravenous lorazepam can be 
given quickly to children with CSE, although it took 
3 min longer to give than rectal diazepam did; however, 
this should not mean that intravenous lorazepam is 
slower to reach the brain. The rate of absorption of 
diazepam through the rectal mucosa is such that the 
speed of the delivery of lorazepam and diazepam to the 
brain are likely to be similar.31 
We found that similar proportions of patients whose 
episodes were treated with adequate doses of rectal 
diazepam before they arrived at hospital continued to have 
seizure activity on arrival at accident and emergency, 
without an increased risk of respiratory depression, as 
those patients who were given inadequate doses. In 
hospital, giving an adequate dose of AED was independently 
associated with an increased likelihood of seizure 
termination; therefore, if rectal diazepam has to be used, 
we recommend that it be given at an adequate dose. 
The APLS guideline recommends that a second dose 
of benzodiazepine is given in the accident and emergency 
setting. However, only 20% of children in our cohort had 
seizure termination after a second dose, which calls this 
strategy into question. Furthermore, giving a second 
dose might result in excessive benzodiazepine load and 
associated respiratory depression, particularly when the 
patient has had prehospital treatment. Previously 
reported respiratory depression after more than two 
doses of benzodiazepine6,32 was conﬁ rmed in this study, 
irrespective of the adequacy of the initial dose. The 
ﬁ nding that worse socioeconomic status contributes to 
respiratory depression highlights a potential vulnerability 
for ill health.33 The mechanism through which this 
association might occur is unclear. We hypothesise that 
it might be related to the reduced ability of parents to 
recognise and treat sickness and the decreased respiratory 
reserve in sick children; socioeconomic deprivation is 
associated with increased diﬃ  culties in parenting31 and 
childhood respiratory problems.34,35 IMD2004 score 
increases with socioeconomic deprivation (worsening 
socioeconomic status).1 The restricted eﬀ ectiveness of 
the second dose of benzodiazepine given in accident and 
emergency might be related to benzodiazepine receptor 
resistance, which increases with seizure length.36–38 These 
Articles
702 www.thelancet.com/neurology   Vol 7   August 2008
data favour the restriction of benzodiazepine treatment 
to two doses, irrespective of where the ﬁ rst dose was 
administered.
The APLS guidelines recommend that rectal 
paraldehyde is used after benzodiazepine therapy has 
failed. However, our results show that current practice 
diﬀ ers: almost a half of the children received phenytoin. 
The absence of fosphenytoin in the treatment of CSE 
might be related to its exclusion from the APLS and 
NICE guidelines.8,9 The only predictor of seizure 
termination after second-line therapy was the choice of 
antiepileptic drug: children who received phenytoin were 
about nine times more likely to have seizure termination 
within 10 min of treatment than the children who were 
treated with rectal paraldehyde were. Therefore, the 
treatment of children with CSE with rectal paraldehyde 
seems unjustiﬁ ed, particularly if intravenous access has 
been secured. 
Because our study was observational with no prespeciﬁ ed 
plan for management of patients, our ﬁ ndings—which 
would support changes in the guidelines for 
pharmacological interventions and highlight the 
importance of early, aggressive treatment of CSE—should 
be conﬁ rmed with controlled trials. However, the 
recruitment of suﬃ  cient numbers of patients could be 
problematic, there would be substantial cost implications, 
and there are potential ethical diﬃ  culties with such 
studies. Owing to the clinical and educational implications 
of our study, an update of the current guidelines for the 
treatment of childhood CSE that incorporates a Cochrane 
Review of the topic would be timely. 
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